TLR agonist treatment induced pro-inflammatory cytokines and NS3 pre-treatment does not induce immune tolerance.
Ayilam Ramachandran Rajalakshmy
Jambulingam Malathi
Hajib Naraharirao Madhavan
10.1371/journal.pone.0125419.g010
https://plos.figshare.com/articles/figure/_TLR_agonist_treatment_induced_pro_inflammatory_cytokines_and_NS3_pre_treatment_does_not_induce_immune_tolerance_/1411843
<p>Microglia was exposed to 50 ng/ml of Pam2CSK4 and Pam3CSK4 and pro-inflammatory cytokine expressions were measured by ELISA. <b>(A and B)</b> Pam2CSK4 treatment induced IL-6 and TNF-α production at 3 and 16 hr time point. <b>(C and D)</b> Similarly Pam3CSK4 treatment induced IL-6 and TNF-α production. Microglial cells were pre-treated with 20 ng/ml of NS3 protein for 16 hrs before 6 hr NS3 treatment to study the immune tolerance induction by NS3. <b>(E)</b> There was no significant difference observed for TNF-α production inNS3 exposed and NS3 pre-treated cells. The data is expressed as mean (n = 3) ± SE, *p< 0.05.</p>
2015-05-12 02:50:40
NS 3
Tumor nicrosis factor
HCV NS 3 protein
Receptor Ligand Treatment Furnished Immune Tolerance BackgroundRecent evidence
TLR agonists Pam 3CSK
hepatitis C Virus NS 3 Mediated Microglial Inflammation
ligands Pam 2CSK
nf
Hepatitis C virus
elisa
Nuclear Factor kappaB
microglial cell line CHME 3.MethodsIL
NS 3 protein
cytokine gene expression
cns
tnf
NS 3. TLR ligand treatment
facs